Dysgeusia
Conditions
Interventions
Experimental group: 59 adult patients will receive a new formulation of zinc supplementation (once a day orally), in suspension presentation, containing chelated zinc (bisciglinate) at a dose of 20mg
Sponsors
Liga Norte Riograndense Contra o Câncer
Liga Norte Riograndense Contra o Câncer
Eligibility
Age
19 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with head and neck cancer; age between 19 and 65 years; under radiotherapy treatment, of both genders.
Exclusion criteria
Exclusion criteria: Gastrointestinal tract disorders; exclusive alternative food route, such as total parenteral nutrition (TPN) and enteral nutritional therapy (ENT); Exocrine pancreatic insufficiency; Tongue or palate demolition surgery; Sjögren's syndrome, considering that the pathophysiology of this disease can affect the salivary glands and impair taste; Diagnosis for Covid-19 with presence of dysgeusia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the degree of dysgeusia obtained between time T1 and T30 of zinc supplementation and to compare the experimental and control groups after 30 days of radiotherapy using the supplement.;Measure dysgeusia by the perception of flavors such as “sweet, salty, sour, bitter and tasteless” and the intensity in the following variants: “very strong, strong, moderate, weak, very weak”, through sensory analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| To analyze adherence to supplementation assessed by the Morisky-Green scale and vial count.;Follow the weight monitored by the nutritional assessment.;Assess food acceptance according to the percentage obtained by the validated tool BRASPEN | — |
Countries
Brazil
Contacts
Public ContactKleyton Medeiros
Liga Norte Riograndense Contra o Câncer
Outcome results
None listed